Price movement over the last 24 hours
Acadia Healthcare Company Inc vs Danaher Corporation — how do they compare? Acadia Healthcare Company Inc trades at $30.77 (market cap $2.94B), while Danaher Corporation trades at $191.43 (market cap $137.44B). The key difference: Danaher Corporation is far larger — about 46.7× Acadia Healthcare Company Inc's market cap, and Danaher Corporation pays a 0.82% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | DHR | |
|---|---|---|
Market Cap | $2.94B | $137.44B |
Sector | Health | Health |
52-Week High | $31.92 | $242.05 |
52-Week Low | $11.68 | $161.91 |
Enterprise Value | $5.45B | $150.22B |
Dividend Yield | — | 0.82% |
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
Danaher (DHR) trades at $193.62, down 2.18% today but remains in a bullish technical trend with strong support near $190. The company demonstrates solid fundamentals with a 58.94% gross margin and consistent earnings beats in recent quarters. Recent news highlights strategic collaborations and a pending acquisition of Masimo, approved by shareholders in May 2026, signaling growth initiatives.
The outlook is positive with a consensus price target of $214.73, implying 11% upside. Key risks include revenue stagnation and a high P/E ratio of 37.52. Analyst sentiment is strongly bullish (69% buy ratings), but investors should monitor execution on acquisitions and bioprocessing demand trends for sustained momentum.
Trailing returns across standard periods
Latest headlines on both assets
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →